Meta-Analysis Open Access
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 171-185
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.171
Rs3746444 T>C locus in miR-499 increases the susceptibility to hepatocellular carcinoma: A meta-analysis 14812 subjects
Jia-Kai Jiang, Department of General Surgery, Changzhou No. 3 People’s Hospital, Changzhou 213000, Jiangsu Province, China
Han-Shen Chen, Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350000, Fujian Province, China
Wei-Feng Tang, Department of Cardiothoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, China
Yu Chen, Jing Lin, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China
Yu Chen, Jing Lin, Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China
Yu Chen, College of Chemistry, Fuzhou University, Fuzhou 350000, Fujian Province, China
ORCID number: Jing Lin (0000-0002-9025-1721).
Author contributions: Jiang JK and Chen HS contributed to this manuscript equally. Jiang JK, Lin J, Chen Y contributed to the conception of the study; Chen HS and Tang WF contributed significantly to the analysis and manuscript preparation; Jiang JK, Chen Y performed the data analyses and wrote the manuscript; HS Chen and Lin J helped perform the analysis with constructive discussions.
Supported by Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy, No. 2020Y2012; the Startup Fund for Scientific Research, Fujian Medical University, No. 2019QH1071; the Science and Technology Supporting Project of Changzhou City, No. CE20205034; Joint Funds for the Innovation of Science and Technology, Fujian Province, No. 2021Y9227; and the National Natural Science Foundation of China, No. U1705282.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing Lin, MA, Doctor, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Jin’an District, Fuzhou 350000, Fujian Province, China. 423559148@qq.com
Received: October 1, 2022
Peer-review started: October 1, 2022
First decision: October 20, 2022
Revised: October 26, 2022
Accepted: November 28, 2022
Article in press: November 28, 2022
Published online: January 15, 2023
Processing time: 100 Days and 18.6 Hours

Abstract
BACKGROUND

Recently, many investigations have suggested that the rs3746444 T>C locus in the microRNA (miR)-499 gene may contribute to the occurrence of cancer. However, reports on the association between rs3746444 and hepatocellular carcinoma (HCC) are conflicting.

AIM

To further understand and explore the potential correlation between the single-nucleotide polymorphism of rs3746444 and the incidence of HCC.

METHODS

In this meta-analysis, we obtained electronic literature by searching the PubMed, Embase and Chinese BioMedical Disc databases (through May 20, 2022). All eligible case-control, prospective cohort or nested case-control studies with sufficient data for calculating the odds ratios with their 95% confidence intervals were included.

RESULTS

Ultimately, a total of 17 independent studies were included. We identified that rs3746444 was associated with the development of HCC (C vs T: P = 0.019 and CC/CT vs TT: P = 0.016). In Asian individuals, rs3746444 was associated with susceptibility to HCC (C vs T: P = 0.013 and CC/CT vs TT: P = 0.016). In addition, this study identified that the miR-499 rs3746444 locus was associated with susceptibility to HCC in the normal/healthy control subgroup (C vs T: P = 0.034 and CC/CT vs TT: P = 0.024).

CONCLUSION

In summary, this meta-analysis highlights that rs3746444 in the miR-499 gene is involved in the occurrence of HCC, especially in Asian individuals.

Key Words: Polymorphism; MicroRNA-499; Hepatocellular carcinoma; Meta-analysis; Susceptibility

Core Tip: Many investigations have suggested that the rs3746444 T>C locus in the microRNA (miR)-499 gene may contribute to the occurrence of cancer. However, reports on the association between rs3746444 and hepatocellular carcinoma (HCC) are conflicting. This meta-analysis highlights that rs3746444 in the miR-499 gene is involved in the occurrence of HCC, especially in Asian individuals.
INTRODUCTION

In 2020, liver cancer (LC) was the seventh most frequent malignancy, with 905677 new cases worldwide[1]. Accordingly, LC is ranked as the second leading cause of malignancy-related deaths, as it has resulted in death for 830180 individuals[1]. The incidence rates of LC and LC-related deaths remain higher in China than other parts of the world[2]. Hepatocellular carcinoma (HCC) is the predominant subtype of LC, accounting for approximately 75%-85% of primary LC cases[3]. Overall, the survival rate of HCC remains poor. To date, the etiology of HCC is not well established. Although it has been reported that chronic virus infection[4], type 2 diabetes[5,6], obesity[7,8], smoking[9,10], heavy alcohol intake[11-13] and aflatoxin-contaminated food stuffs[14] may contribute to the occurrence of HCC, other risk factors may also lead to the development of HCC, such as hereditary factors[15-18].

MicroRNAs (miRs) are noncoding RNAs of approximately 22 nucleotides in size. They may be implicated in the regulation of target genes and are involved in a number of cellular processes (e.g., growth, proliferation, differentiation, apoptosis, migration and invasion)[19-24]. Recently, several investigations have reported that the expression profiling of serum miRs could be used as a marker for hepatitis C virus-related cases of HCC[25]. Variants within miRs may alter target recognition, transcription, or posttranscriptional processing and then lead to malignant diseases[26]. Additionally, most of the established miRs may influence many target genes; single-nucleotide polymorphisms (SNPs) in miRs could affect the level of multifarious proteins. MiR-499 is located within chromosome 20q. MiR-499 is involved in infection and inflammatory diseases[27]. Rs3746444 T>C in miR-499 was identified to be correlated with the development of ankylosing spondylitis[28], arthritis susceptibility[29], and bronchial asthma[27].

Additionally, a number of investigations have suggested that the rs3746444 SNP in miR-499 may contribute to the occurrence of cancer. Liu et al[30] reported that miR-499-5p could promote the metastasis of colorectal cancer and might be used as a vital target for colorectal cancer therapy. Additionally, a previous study identified that in HepG2 cells, miR-499 could inhibit the level of the E26 transformation specific sequence 1, which is an important proto-oncogene in the development of HCC[31]. The miR-499 variant rs3746444 has been suggested to play an important role in the occurrence of various malignancies, such as adenocarcinoma of the esophagogastric junction[32], prostate cancer[33], cervical squamous cell carcinoma[34], oral squamous cell cancer[35], and lung cancer[36]. Recently, a number of studies have focused on the relationship between rs3746444 in miR-499 and HCC[36-40]; however, the obtained findings are conflicting. Several meta-analyses also reported controversial results. Some pooled analyses have suggested that the rs3746444 C allele could not confer a risk to HCC[41-44]. However, other publications have reported that the rs3746444 C allele may contribute to the occurrence of HCC[40,45-47]. These controversial findings may be due to the limited sample sizes included in these analyses. Recently, some case-control studies have been conducted to further explore this potential association[48-50]. An updated meta-analysis is needed to shed new light on the relationship between rs3746444 in miR-499 and HCC regarding all available publications. Therefore, this meta-analysis involved a large sample size to verify whether the miR-499 rs3746444 SNP could influence the occurrence of HCC. And these possible relationships might be beneficial to the prevention of liver carcinogenesis.

MATERIALS AND METHODS
Study research

In this meta-analysis, we obtained electronic literature by searching the PubMed, Embase and Chinese BioMedical Disc (CBM) databases (through May 20, 2022). We used the following keywords: (SNP OR variant OR polymorphism) AND (neoplasm OR carcinoma OR tumor OR cancer) AND (hepatocellular OR liver) AND (microRNA499 OR miR499 OR microRNA-499 OR miR-499 OR rs3746444). The references included in the retrieved publications and relevant reviews, as well as published meta-analyses, were hand-searched to obtain more related data. Due to no restriction on language, a large amount of data was collected. We also cited high-quality articles in Reference Citation Analysis (https://www.referencecitationanalysis.com).

Inclusion and exclusion criteria

The inclusion criteria for the eligible literature were as follows: (1) Assessing the relationship of rs3746444 in miR-499 with HCC susceptibility; (2) Full-text study; (3) Designed as a case-control study, a prospective cohort or a nested case-control study; and (4) Sufficient data could be used to calculate the odds ratios (Ors) with their 95% confidence intervals (CIs). When a publication contained more than one investigation, it was treated as an independent case-control study. Accordingly, letters, reviews, comments, non-case-control studies, studies that violated Hardy-Weinberg equilibrium (HWE), literature without sufficient data and duplicated data were excluded.

Data extraction

Two authors (Jiang JK and Lin J) reviewed the eligible literature and extracted the data independently. The following information was collected: The first author, year of publication, mean age (years), sex (male, %), drinking status (%), smoking status (%), country/ethnicity, hepatitis B surface antigen (HBsAg) (positive, %), number of subjects, HWE, genotyping method and genotype data. In a case of a conflicting assessment, another author (Tang WF) took part in a discussion until a consensus opinion was obtained.

Statistical methods

The results of this meta-analysis were assessed in four genetic models: A dominant model (CC/TC vs TT), recessive model (CC vs TT/TC), homozygote comparison (CC vs TT) and allelic model (C vs T). The correlation between rs3746444 in miR-499 and HCC susceptibility was determined by using Ors and the corresponding 95%CIs. The heterogeneity among the eligible studies was assessed by using the I2 test and Q test. For heterogeneity, the level of significance was P < 0.1 and/or I2≥ 50%. When it was significant, we used a random-effects model (DerSimonian and Laird) to assess the association between rs3746444 in miR-499 and HCC susceptibility[51,52]. Otherwise, we used a fixed-effects model (Mantel-Haenszel) to determine the potential association[53]. In this study, a Galbraith radial plot was used to confirm the source of the heterogeneity. Sensitivity analysis was performed to explore whether an individual investigation might significantly influence the assessment. We used Egger’s test and Begg’s funnel plots to measure the possible bias among the publications. For publication bias, the level of significance was P < 0.1. STATA 12.0 software (Stata Corp., College Station, Texas) was used to conduct statistical analysis. All P-values were measured with two-sided tests. By using Power-SampleSize software, the power value (α = 0.05) was also used to assess the stability of our study[54]. We used the Newcastle-Ottawa Quality Assessment Scale to assess the quality of eligible studies and defined scores ≥ 7 stars as high-quality studies[55].

RESULTS
Study characteristics

An electronic search of the CBM, PubMed and Embase databases obtained 117 publications. After the titles or abstracts were reviewed by two authors (Jiang JK and Lin J), 47 duplicates were removed. Fifty articles were excluded based on the inclusion criteria (Figure 1). Thus, 20 articles were reviewed in full text. Three publications were included after reading the references of eligible articles. However, 11 case-control studies were excluded for violating HWE. Finally, 13 publications with 17 independent case-control studies focusing on the relationship between the rs3746444 polymorphism and HCC risk were included[40,48,50,56-65].

Figure 1
Open in New Tab   Full Size Figure   Download Figure
Figure 1 Flow diagram of the meta-analysis. CBM: Chinese BioMedical Disc; miRNA: MicroRNA.

These included studies were published between 2012 and 2020, and in the eligible case-control studies, the participant number ranged from 100 to 1507. Table 1 shows the included terms in the eligible studies. In summary, 7 case-control studies involving Caucasian individuals were found[50,56-58], and the others focused on Asian individuals[40,48,59-65]. The distributions of the rs3746444 genotypes and alleles in the miR-499 SNP and the results of the quality assessment are summarized in Tables 1 and 2.

Table 1 Characteristics of the studies in meta-analysis.
Ref.
Country
Ethnicity
Study design
Sex, male (%); case/control
Mean age (yr); case/control
Smoking (%); case/control
Drinking (%); case/control
HBsAg, positivee (%); case/control
Number cases/controls
Type of control
Case
Control
HWE
TT
TC
CC
TT
TC
CC
Zhang et al[59], 2016ChinaAsianHB70.29/56.2956.13/54.9634.29/30.7950.29/36.09NA175/302Normal or healthy control115491119787180.052
Li et al[60], 2015ChinaAsianPB75.56/75.56≥ 55 yr, 55.26/≥55 yr, 53.3836.47/31.5847.37/36.4741.35/12.03266/250Normal or healthy control150922416683170.140
Yan et al[61], 2015ChinaAsianPB77.74/63.41≥ 55 yr, 55.84/≥ 55 yr, 45.4347.81/42.6858.76/40.5561.31/10.37274/328Normal or healthy control1479829188112280.060
Qi et al[62], 2014ChinaAsianPB83.8/83.850.7/49.638.9/NA27.4/NA83.2/0.0314/406Normal or healthy control195117230110140.157
Chu et al[63], 2014ChinaAsianHB72.34/74.78< 45 yr, 5.05, 45-59 yr, 30.85, ≥ 60 yr, 63.83/< 45 yr, 7.12, 45-59 yr, 40.06, ≥ 60 yr, 52.8242.55/33.2336.17/40.3642.55/13.23188/337Normal or healthy control1196092815510.321
Zhou et al[64], 2012ChinaAsianPB82.8/NA52.1/NANA/NANA/NANA/NA186/483Normal or healthy control141414371100120.100
Xiang et al[65], 2012ChinaAsianHB82/3948.55/47.02NA/NANA/NANA/NA100/100Hepatitis or virus related control3640245235130.081
Xiang et al[65], 2012ChinaAsianHB82/5048.55/45.12NA/NANA/NANA/NA100/100Normal or healthy control3640245436100.284
Kim et al[40], 2012KoreaAsianPBNA/NANA/NANA/NANA/NANA/NA159/201NA/NA1094731207470.278
Zhang et al[48], 2020ChinaAsianHB89.90/90.4753.17/53.7235.96/35.4329.11/16.0370.55/9.21584/923Normal or healthy control40915412669230220.673
Toraih et al[50], 2016EgyptCaucasianHBNA/NANA/NANA/NANA/NANA/NA60/150Normal or healthy control282395766270.307
Fteah et al[56], 2019, Abdel-Hamid et al[57], 2018EgyptCaucasianHB80.00/81.3350.12/50.1154.7/0.0NA/NANA/NA75/75Normal or healthy control413223130140.175
EgyptCaucasianHB78.0/70.055.8/54.434.0/34.0NA/NA6.0/0.050/50Normal or healthy control332151623110.617
Al-Qahtani et al[58], 2017Saudi ArabiaCaucasianHBNA/68.4NA/40.29NA/NANA/NANA/100.00145/585Hepatitis or virus related control487027219273930.607
Al-Qahtani et al[58], 2017Saudi ArabiaCaucasianHBNA/79.7NA/36.33NA/NANA/NANA/100.00145/222Hepatitis or virus related control48702787100350.486
Al-Qahtani et al[58], 2017Saudi ArabiaCaucasianHBNA/94.25NA/37.49NA/NANA/NANA/0.0145/400Normal or healthy control487027148187650.647
Al-Qahtani et al[58], 2017Saudi ArabiaCaucasianHBNA/96.30NA/30.80NA/NANA/NANA/0.0145/600Normal or healthy control487027216291930.758
PB: Population-based; HB: Hospital-based; NA: Not available; HBsAg: Hepatitis B surface antigen; HWE: Hardy-Weinberg equilibrium.
Table 2 Quality assessment of the meta-analysis.
Ref.
Selection
Comparability of the cases and controls
Exposure
Total stars
Adequate case definition
Representativeness of the cases
Selection of the controls
Definition of Controls
Ascertainment of exposure
Same ascertainment method for cases and controls
Non-response rate
Zhang et al[59], 2016★★-★★★★★-7
Li et al[60], 2015★★★★★★★★-8
Yan et al[61], 2015★★★★★★★-7
Qi et al[62], 2014★★★★★★★-7
Chu et al[63], 2014★★-★★★★★-7
Zhou et al[64], 2012★★★★★★★★-8
Xiang et al[65], 2012★★-★★★★-6
Xiang et al[65], 2012★★-★★★★-6
Kim et al[40], 2012★★★★-★★-6
Zhang et al[48], 2020★★-★★★★★-7
Toraih et al[50], 2016★★-★-★★-5
Fteah et al[56], 2019★★-★★★★★-7
Abdel-Hamid et al[57], 2018★★-★★★★★-7
Al-Qahtani et al[58], 2017★★-★-★★-5
Al-Qahtani et al[58], 2017★★-★-★★-5
Al-Qahtani et al[58], 2017★★-★-★★-5
Al-Qahtani et al[58], 2017★★-★-★★-5
Main findings

The main results are summarized in Table 3. When we combined the included case-control studies, we identified that rs3746444 in miR-499 was associated with the development of HCC (C vs T: P = 0.019 and CC/CT vs TT: P = 0.016, Figure 2). In a subgroup analysis by different races, rs3746444 in miR-499 was found to be associated with susceptibility to HCC in the Asian population (C vs T: P = 0.013 and CC/CT vs TT: P = 0.016). When we considered the source of disease, the miR-499 rs3746444 locus was identified to be associated with susceptibility to HCC in normal/healthy control individuals (C vs T: P = 0.034 and CC/CT vs TT: P = 0.024) and hepatitis/virus-related control individuals (C vs T: P = 0.007, CC vs TT: P = 0.014 and CC/CT vs TT: P = 0.018).

Figure 2
Open in New Tab   Full Size Figure   Download Figure
Figure 2 Meta-analysis of the relationship between rs3746444 in microRNA-499 single-nucleotide polymorphism with the risk of hepatocellular carcinoma (C vs T, random-effects model). OR: Odds ratio; CI: Confidence interval.
Table 3 Summary of results of the meta-analysis from different comparative genetic model.
Genetic comparison
Population
OR (95%CI)
P value
Test of heterogeneity
Model
Power value
P value
I2
C vs TAll1.21 (1.03-1.41)0.019< 0.00174.9%R1.000
Ethnicity
Asians1.32 (1.06-1.64)0.013< 0.00179.4%R1.000
Caucasians1.06 (0.86-1.32)0.5860.01064.2%R-
Study design
HB1.25 (1.01-1.54)0.039< 0.00179.0%R0.999
PB1.13 (0.90-1.42)0.2850.02763.6%R-
Controls
Normal or healthy control1.22 (1.02-1.48)0.034< 0.00177.2%R0.998
Hepatitis or virus related control1.27 (1.07-1.52)0.0070.19239.4%F0.785
NA0.71 (0.49-1.04)0.080----
Nos quality assessment
≥ 7.01.24 (0.97-1.58)0.088< 0.00181.2%R
< 7.01.17 (0.96-1.43)0.2160.00466.2%R
CC vs TTAll1.33 (0.98-1.80)0.0710.00257.3%R-
Ethnicity
Asians1.48 (0.97-2.26)0.0730.02154.0%R-
Caucasians1.16 (0.72-1.87)0.5340.00865.3%R-
Study design
HB1.44 (0.97-2.16)0.074< 0.00167.7%R-
PB1.20 (0.83-1.73)0.3440.5510.0%F-
Controls
Normal or healthy control1.31 (0.88-1.93)0.1830.00162.8%R-
Hepatitis or virus related control1.56 (1.10-2.23)0.0140.32910.1%F0.725
NA0.47 (0.12-1.87)0.285----
Nos quality assessment
≥ 7.01.26 (0.71-2.25)0.4360.0267.3%R
< 7.01.41 (1.01-1.96)0.0140.08643.8%R0.881
CC/CT vs TTAll1.26 (1.04-1.51)0.016< 0.00170.0%R0.999
Ethnicity
Asians1.34 (1.06-1.71)0.016< 0.00175.7%R0.999
Caucasians1.12 (0.83-1.51)0.4680.02159.7%R-
Study design
HB1.32 (1.03-1.70)0.031< 0.00173.1%R0.999
PB1.16 (0.87-1.54)0.3090.01467.9%R-
Controls
Normal or healthy control1.29 (1.03-1.60)0.024< 0.00172.5%R0.999
Hepatitis or virus related control1.37 (1.06-1.77)0.0180.3970.0%F0.697
NA0.68 (0.44-1.05)0.084----
Nos quality assessment
≥ 7.01.33 (1.01-1.76)0.044< 0.00178.2%R0.997
< 7.01.18 (0.92-1.51)0.1910.02656.1%R
CC vs TT/CTAll1.21 (0.96-1.53)0.1090.04939.4%R-
Ethnicity
Asians1.37 (0.95-1.97)0.0950.07742.1%R-
Caucasians1.09 (0.87-1.37)0.4480.12739.6%F-
Study design
HB1.25 (0.93-1.70)0.1450.01453.7%R-
PB1.15 (0.80-1.65)0.4490.6400.0%F-
Controls
Normal or healthy control1.18 (0.87-1.60)0.2840.02947.5%R-
Hepatitis or virus related control1.36 (0.99-1.87)0.0610.4210.0%F-
NA0.53 (0.14-2.10)0.368----
Nos quality assessment
≥ 7.01.08 (0.68-1.71)0.7440.02753.7%R
< 7.01.30 (1.05-1.60)0.0170.28418.5%F0.734
Bold values are statistically significant (P < 0.05). F: Indicates fixed model; R: Indicates random model; PB: Population-based; HB: Hospital-based; NA: Not available; OR: Odds ratio; CI: Confidence interval; NOS: Newcastle-Ottawa Scale.
Sensitivity analysis

To confirm the stability of our findings, we conducted a sensitivity analysis in this meta-analysis. We deleted an individual study in turn and calculated the Ors and CIs of the remaining studies to determine the influence of each datum. The findings suggested that these evaluations could not be altered by any eligible study (Figure 3).

Figure 3
Open in New Tab   Full Size Figure   Download Figure
Figure 3 Sensitivity analysis of the influence of C vs T genetic model (random-effects model). CI: Confidence interval.
Publication bias

By using Begg’s and Egger’s tests, publication bias among the eligible studies was determined. There was no significant bias among the eligible studies (Figure 4A, P > 0.1, data not shown).

Figure 4
Open in New Tab   Full Size Figure   Download Figure
Figure 4 Plot of meta-analysis (C vs T, random-effects model). A: Begg’s funnel; B: Galbraith radial. OR: Odds ratio.
Heterogeneity

In this meta-analysis, significant heterogeneity was identified. We conducted stratified analyses to explore the source of heterogeneity. Newcastle-Ottawa Scale (Nos) was used to evaluate the literature quality. We found an association between hospital-based (HB) studies, high-quality studies (Nos ≥ 7.0), Asian individuals, and normal/healthy control subgroups and significant heterogeneity. The Galbraith radial plot test suggested that 4 outliers[40,56,63,65] might contribute to the significant heterogeneity (Figure 4B).

The power of the present study (α = 0.05)

By using Power-Sample Size software, the power value (α = 0.05) was also used to assess the stability of our study. As summarized in Table 3, in the overall comparison, the power value was more than 0.8 in the allele and dominant genetic models. In the subgroup analyses, the power value was more than 0.8 in Asian individuals and the normal/healthy control subgroups in the allele genetic model and in Asian individuals and the normal/healthy control subgroups in the dominant genetic model.

DISCUSSION

Recently, rs3746444 in miR-499 and its importance to the occurrence of HCC have been extensively investigated. However, several meta-analyses reported controversial results, which might be due to the limited sample sizes included in these analyses. Recently, some case-control studies have been conducted to further explore this potential association in different populations. Thus, an updated meta-analysis should be conducted to shed new light on the relationship between rs3746444 in miR-499 and HCC. As summarized in Table 3, we identified that rs3746444 in miR-499 was associated with the development of HCC in the allele and the dominant genetic models (the value of power ≥ 0.8).

The merit of this updated meta-analysis was that the present pooled analysis included a larger sample size to verify whether the miR-499 rs3746444 SNP could influence the occurrence of HCC. In this study, we identified that the miR-499 rs3746444 SNP could confer a risk to HCC. Some meta-analyses have focused on the potential correlation between rs3746444 in miR-499 and the risk of HCC. A previous pooled analysis suggested that the rs3746444T allele in the miR-499 gene could not play a vital role in the tumorigenesis of HCC[42]. However, other meta-analyses reported that rs3746444 in miR-499 might confer susceptibility to HCC[40,45-47]. Additionally, some more recent case-control studies have been conducted to explore the potential association between rs3746444 in the miR-499 SNP and the risk of HCC[48-50]. The potential association was more controversial. Thus, we included 28 independent case-control studies with 5948 cases and 8864 controls and conducted an updated meta-analysis to focus on the relationship between rs3746444 in the miR-499 SNP and the risk of HCC. In this study, we identified that the miR-499 rs3746444 SNP could confer a risk to HCC.

Toraih et al[26] reported that in silico data analysis, the T to C substitution in the miR-499 rs3746444 SNP did not prominently affect the structure of the hairpin loop. Functional prediction revealed that different miR-499 rs3746444 alleles have different targets. The miR-499 rs3746444*C allele only has 58.2% of the gene targets of the rs3746444*T variant and generates 763 new gene targets. The miR-499 gene can target both alcohol dehydrogenase 1 beta polypeptide (ADH1B) and aldehyde dehydrogenase 1 family member A3 (ALDH1A3) genes. Pettinelli et al[66] suggested that hepatic ALDH1A3 was expressed at lower levels and was inversely correlated with the level of plasma retinol in nonalcoholic steatohepatitis cases, which may alter the risk for HCC. Recently, some studies have identified that the ADH1B gene may be involved in the development of HCC[67-69]. A previous study indicated that rs3746444 in miR-499 was correlated with susceptibility to ulcerative colitis and that the expression of miR-499 was decreased (5-fold) in ulcerative colitis cases with the rs3746444 TC genotype compared with those with the rs3746444 TT variant[70]. Taken together, these results indicate that the rs3746444 C allele in the miR-499 gene could decrease the expression of the miR-499 gene and alter the levels of the ADH1B and ALDH1A3 genes. Finally, this SNP could be implicated in the occurrence of HCC. However, the relationship between rs3746444 in miR-499 and HCC in different subgroups could not be well explained. In the future, more attention should be given to the potential mechanism by which hepatitis B virus infection acts in different ethnicities or statuses.

Since significant heterogeneity was found in this meta-analysis, subgroup analysis was performed to observe the major source of heterogeneity. The findings of the subgroup analysis indicated that the normal/healthy control, Asian and HB subgroups could greatly increase the heterogeneity. Additionally, the Galbraith radial plot identified 4 outliers[40,56,63,65], which could contribute to the major source of heterogeneity.

There are some limitations in this meta-analysis. First, the electronic literature was only searched in the PubMed, Embase and CBM databases, and bias might have occurred. Second, all investigations have been conducted in Caucasian and Asian populations; thus, our findings were only appropriate for these populations. Third, due to insufficient data (e.g., HBsAg, drinking, smoking, sex, age, body mass index and lifestyle) in this study, we did not consider these factors in the subgroup analysis. Fourth, due to the lack of environmental factors, we also did not take into account gene-environment interactions. Fifth, in this meta-analysis, significant heterogeneity was identified. Sixth, we did not pay close attention to the expression level of target genes, which could be controlled by rs3746444 T>C locus. Finally, in this study, we only included the relationship between rs3746444 in miR-499 and HCC risk. The potential role of other vital miR loci can’t be ignored.

CONCLUSION

In summary, this meta-analysis highlights that rs3746444 in miR-499 is involved in the occurrence of HCC, especially in Asian individuals. In the future, more investigations are needed to confirm our results.

ARTICLE HIGHLIGHTS
Research background

This meta-analysis highlights that rs3746444 in microRNA (miR)-499 is involved in the occurrence of hepatocellular carcinoma (HCC), especially in Asian individuals. These possible relationships might be beneficial to the prevention of liver carcinogenesis. In the future, more investigations are needed to confirm.

Research motivation

Recently, a number of studies have focused on the relationship between rs3746444 in miR-499 and HCC. However, the obtained findings are conflicting.

Research objectives

In summary, this meta-analysis highlights that rs3746444 in miR-499 is involved in the occurrence of HCC, especially in Asian individuals. In the future, more investigations are needed to confirm our results.

Research methods

This meta-analysis involved a large sample size to verify whether the miR-499 rs3746444 single-nucleotide polymorphism could influence the occurrence of HCC. These possible relationships might be beneficial to the prevention of liver carcinogenesis.

Research results

Reports on the association between rs3746444 and HCC are conflicting.

Research conclusions

The results of this meta-analysis were assessed in four genetic models: A dominant model (CC/TC vs TT), recessive model (CC vs TT/TC), homozygote comparison (CC vs TT) and allelic model (C vs T). The correlation between rs3746444 in miR-499 and HCC susceptibility was determined by using odd ratios and the corresponding 95% confidence intervals. We used a random-effects model (DerSimonian and Laird) to assess the association between rs3746444 in miR-499 and HCC susceptibility. Otherwise, we used a fixed-effects model (Mantel-Haenszel) to determine the potential association. We used the Newcastle-Ottawa Quality Assessment Scale to assess the quality of eligible studies and defined scores ≥ 7 stars as high-quality studies.

Research perspectives

Reports on the association between rs3746444 and HCC are conflicting. This meta-analysis highlights that rs3746444 in miR-499 is involved in the occurrence of HCC, especially in Asian individuals. These possible relationships might be beneficial to the prevention of liver carcinogenesis.

ACKNOWLEDGEMENTS

We wish to thank Dr. Hao Ding (Affiliated People’s Hospital of Jiangsu University, China) for technical support.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Keikha M, Iran; Skrypnik D, Poland S-Editor: Wang JJ L-Editor: A P-Editor: Wang JJ

References
1.  Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 50630]  [Cited by in F6Publishing: 55370]  [Article Influence: 18456.7]  [Reference Citation Analysis (157)]
2.  Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11444]  [Cited by in F6Publishing: 12906]  [Article Influence: 1613.3]  [Reference Citation Analysis (2)]
3.  Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 53206]  [Cited by in F6Publishing: 53621]  [Article Influence: 8936.8]  [Reference Citation Analysis (124)]
4.  Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254-1264.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 43]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
5.  Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol. 2019;25:6322-6341.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 16]  [Cited by in F6Publishing: 20]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
6.  Michel M, Kalliga E, Labenz C, Straub BK, Wörns MA, Galle PR, Schattenberg JM. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. Z Gastroenterol. 2020;58:57-62.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
7.  Chong YC, Lim TE, Fu Y, Shin EM, Tergaonkar V, Han W. Indian Hedgehog links obesity to development of hepatocellular carcinoma. Oncogene. 2019;38:2206-2222.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
8.  Chen Y, Zhang F, Zhao Y, He K, Zheng X, Pan Y, Shao D, Shang P, Yang Y, Zhang D, Xie Y, Yao X, Chen L, Li J, Zhang X. Obesity-associated miR-27a upregulation promotes hepatocellular carcinoma metastasis through suppressing SFRP1. Onco Targets Ther. 2018;11:3281-3292.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 8]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
9.  Guarino M, Dufour JF. Smoking favours hepatocellular carcinoma. Ann Transl Med. 2019;7:S99.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
10.  Li CL, Lin YK, Chen HA, Huang CY, Huang MT, Chang YJ. Smoking as an Independent Risk Factor for Hepatocellular Carcinoma Due to the α7-Nachr Modulating the JAK2/STAT3 Signaling Axis. J Clin Med. 2019;8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 20]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
11.  Mukaiya M, Nishi M, Miyake H, Hirata K. Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology. 1998;45:2328-2332.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S. Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res. 1996;87:867-873.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 17]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
13.  Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol. 2019;71:523-533.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 131]  [Cited by in F6Publishing: 128]  [Article Influence: 25.6]  [Reference Citation Analysis (0)]
14.  Hifnawy MS, Mangoud AM, Eissa MH, Nor Edin E, Mostafa Y, Abouel-Magd Y, Sabee EI, Amin I, Ismail A, Morsy TA, Mahrous S, Afefy AF, el-Shorbagy E, el-Sadawy M, Ragab H, Hassan MI, el-Hady G, Saber M. The role of aflatoxin-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia Governorate, Egypt. J Egypt Soc Parasitol. 2004;34:479-488.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Yang J, Liu J, Chen Y, Tang W, Bo K, Sun Y, Chen J. Investigation of ICOS, CD28 and CD80 polymorphisms with the risk of hepatocellular carcinoma: a case-control study in eastern Chinese population. Biosci Rep. 2019;39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
16.  Yang J, Liu J, Chen Y, Tang W, Liu C, Sun Y, Chen J. Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study. Medicine (Baltimore). 2019;98:e16266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 11]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
17.  Zhang S, Lin J, Jiang J, Chen Y, Tang W, Liu L. Association between methylenetetrahydrofolate reductase tagging polymorphisms and susceptibility of hepatocellular carcinoma: a case-control study. Biosci Rep. 2019;39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 7]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
18.  Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Chen Y, Liu L. Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population. Onco Targets Ther. 2018;11:4651-4660.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
19.  Wang L, Hu K, Chao Y, Wang X. MicroRNA-1296-5p suppresses the proliferation, migration, and invasion of human osteosarcoma cells by targeting NOTCH2. J Cell Biochem. 2020;121:2038-2046.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 9]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
20.  Hu XH, Zhao ZX, Dai J, Geng DC, Xu YZ. MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27. J Cell Biochem. 2019;120:4665-4674.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 25]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
21.  Zhao X, Lu C, Chu W, Zhang Y, Zhang B, Zeng Q, Wang R, Li Z, Lv B, Liu J. microRNA-214 Governs Lung Cancer Growth and Metastasis by Targeting Carboxypeptidase-D. DNA Cell Biol. 2016;35:715-721.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 18]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
22.  Jian Y, Xu CH, Li YP, Tang B, Xie SH, Zeng EM. Down-regulated microRNA-30b-3p inhibits proliferation, invasion and migration of glioma cells via inactivation of the AKT signaling pathway by up-regulating RECK. Biosci Rep. 2019;39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 18]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
23.  Wang MJ, Zhang H, Li J, Zhao HD. microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2. Biosci Rep. 2018;38.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 20]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
24.  Li J, Jin B, Wang T, Li W, Wang Z, Zhang H, Song Y, Li N. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomark. 2019;26:501-512.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 25]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
25.  Chen LB, Zheng HK, Zhang L, An Z, Wang XP, Shan RT, Zhang WQ. A single nucleotide polymorphism located in microRNA-499a causes loss of function resulting in increased expression of osbpl1a and reduced serum HDL level. Oncol Rep. 2017;38:3515-3521.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
26.  Toraih EA, Hussein MH, Al Ageeli E, Riad E, AbdAllah NB, Helal GM, Fawzy MS. Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma. Respir Res. 2017;18:169.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 12]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
27.  Xu HY, Wang ZY, Chen JF, Wang TY, Wang LL, Tang LL, Lin XY, Zhang CW, Chen BC. Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PLoS One. 2015;10:e0122055.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 29]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
28.  Toraih EA, Ismail NM, Toraih AA, Hussein MH, Fawzy MS. Precursor miR-499a Variant but not miR-196a2 is Associated with Rheumatoid Arthritis Susceptibility in an Egyptian Population. Mol Diagn Ther. 2016;20:279-295.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 30]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
29.  Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, Hu H, Nie Y, Wang X, Wu K, Jin H, Fan D. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis. 2011;32:1798-1805.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 117]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
30.  Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y, Zheng X. MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep. 2012;28:701-706.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 47]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
31.  Tang W, Wang Y, Pan H, Qiu H, Chen S. Association of miRNA-499 rs3746444 A>G variants with adenocarcinoma of esophagogastric junction (AEG) risk and lymph node status. Onco Targets Ther. 2019;12:6245-6252.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
32.  Nouri R, Ghorbian S. Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer. Int Urol Nephrol. 2019;51:811-816.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
33.  Srivastava S, Singh S, Fatima N, Mittal B, Srivastava AN. Pre-microRNA Gene Polymorphisms and Risk of Cervical Squamous Cell Carcinoma. J Clin Diagn Res. 2017;11:GC01-GC04.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 8]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
34.  Zhang E, Xu Z, Duan W, Huang S, Lu L. Association between polymorphisms in pre-miRNA genes and risk of oral squamous cell cancer in a Chinese population. PLoS One. 2017;12:e0176044.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 11]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
35.  Li D, Zhu G, Di H, Li H, Liu X, Zhao M, Zhang Z, Yang Y. Associations between genetic variants located in mature microRNAs and risk of lung cancer. Oncotarget. 2016;7:41715-41724.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 14]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
36.  Akkiz H, Bayram S, Bekar A, Akgöllü E, Üsküdar O. Genetic variation in the microRNA-499 gene and hepatocellular carcinoma risk in a Turkish population: lack of any association in a case-control study. Asian Pac J Cancer Prev. 2011;12:3107-3112.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Wang XH, Wang FR, Tang YF, Zou HZ, Zhao YQ. Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genet Mol Res. 2014;13:5048-5054.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 23]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
38.  Kou JT, Fan H, Han D, Li L, Li P, Zhu J, Ma J, Zhang ZH, He Q. Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection. Oncol Lett. 2014;8:1255-1260.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 25]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
39.  Shan YF, Huang YH, Chen ZK, Huang KT, Zhou MT, Shi HQ, Song QT, Yu ZP, Deng AM, Zhang QY. miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the Chinese population. Genet Mol Res. 2013;12:5365-5371.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 21]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
40.  Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, Kim NK. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 2012;504:92-97.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 79]  [Cited by in F6Publishing: 87]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
41.  Zheng L, Zhuang C, Zhao J, Ming L. Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms and the susceptibility to hepatocellular carcinoma: An updated meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:664-676.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 20]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
42.  Yu JY, Hu F, Du W, Ma XL, Yuan K. Study of the association between five polymorphisms and risk of hepatocellular carcinoma: A meta-analysis. J Chin Med Assoc. 2017;80:191-203.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 12]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
43.  Ye LX, Fu CW, Jiang F, Cui YX, Meng W. [A meta-analysis of microRNA-149, microRNA-499 gene polymorphism and susceptibility to hepatocellular carcinoma]. Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50:445-450.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 2]  [Reference Citation Analysis (0)]
44.  Liu F, Lin H, Cheng Y, Yang L, Liu Y. rs3746444 polymorphism and susceptibility to hepatocellular carcinoma: evidence from published studies. Cell Biochem Biophys. 2014;70:1957-1961.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
45.  Qiu D, Han F, Zhuang H. MiR-499 rs3746444 polymorphism and hepatocellular carcinoma risk: A meta-analysis. J Cancer Res Ther. 2018;14:S490-S493.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 3]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
46.  Yu H, Wang Y, Wang S, Sun N. Association between miR-499 rs3746444 and the susceptibility of hepatocellular carcinoma. Cell Mol Biol (Noisy-le-grand). 2016;62:42-45.  [PubMed]  [DOI]  [Cited in This Article: ]
47.  Zhu SL, Zhong JH, Gong WF, Li H, Li LQ. Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: an updated meta-analysis. Onco Targets Ther. 2016;9:2111-2119.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 6]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
48.  Zhang S, Chen L, Wang Y, Tang W, Chen Y, Liu L. Investigation of the Association of miRNA-499, miRNA-146a, miRNA-196a2 Loci with Hepatocellular Carcinoma Risk: A Case-Control Study Involving 1507 Subjects. DNA Cell Biol. 2020;39:379-388.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 11]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
49.  Farokhizadeh Z, Dehbidi S, Geramizadeh B, Yaghobi R, Malekhosseini SA, Behmanesh M, Sanati MH, Afshari A, Moravej A, Karimi MH. Association of MicroRNA Polymorphisms With Hepatocellular Carcinoma in an Iranian Population. Ann Lab Med. 2019;39:58-66.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 18]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
50.  Toraih EA, Fawz MS, Elgazzaz MG, Hussein MH, Shehata RH, Daoud HG. Combined Genotype Analyses of Precursor miRNA196a2 and 499a Variants with Hepatic and Renal Cancer Susceptibility a Preliminary Study. Asian Pac J Cancer Prev. 2016;17:3369-3375.  [PubMed]  [DOI]  [Cited in This Article: ]
51.  Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39087]  [Cited by in F6Publishing: 44126]  [Article Influence: 2101.2]  [Reference Citation Analysis (1)]
52.  DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26739]  [Cited by in F6Publishing: 29453]  [Article Influence: 775.1]  [Reference Citation Analysis (0)]
53.  Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Tang W, Qiu H, Ding H, Sun B, Wang L, Yin J, Gu H. Association between the STK15 F31I polymorphism and cancer susceptibility: a meta-analysis involving 43,626 subjects. PLoS One. 2013;8:e82790.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 34]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
55.  Wang W, Shao Y, Tang S, Cheng X, Lian H, Qin C. Peroxisome proliferator-activated receptor-γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk. Int J Clin Exp Med. 2015;8:4066-4072.  [PubMed]  [DOI]  [Cited in This Article: ]
56.  Fteah AM, Ahmed AI, Mosaad NA, Hassan MM, Mahmoud SH. Association of MicroRNA 196a and 499 Polymorphisms with Development of Cirrhosis and Hepatocellular Carcinoma Post-HCV Infection in Egyptian Patients. Asian Pac J Cancer Prev. 2019;20:3479-3485.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 4]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
57.  Abdel-Hamid M, Elshaer S, Darwish A. Association of MicroRNA related single nucleotide polymorphisms 196A-2 and 499 with the risk of hepatocellular carcinoma in Egyptian patients. Meta Gene. 2018;16:139-142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 3]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
58.  Al-Qahtani AA, Al-Anazi MR, Nazir N, Wani K, Abdo AA, Sanai FM, Khan MQ, Al-Ashgar HI, Albenmousa A, Al-Hamoudi WK, Alswat KA, Al-Ahdal MN. Association of single nucleotide polymorphisms in microRNAs with susceptibility to hepatitis B virus infection and HBV-related liver complications: A study in a Saudi Arabian population. J Viral Hepat. 2017;24:1132-1142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
59.  Zhang LH, Hao BB, Zhang CY, Dai XZ, Zhang F. Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma. Genet Mol Res. 2016;15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 13]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
60.  Li X, Li K, Wu Z. Association of four common SNPs in microRNA polymorphisms with the risk of hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:9560-9566.  [PubMed]  [DOI]  [Cited in This Article: ]
61.  Yan P, Xia M, Gao F, Tang G, Zeng H, Yang S, Zhou H, Ding D, Gong L. Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:15177-15183.  [PubMed]  [DOI]  [Cited in This Article: ]
62.  Qi JH, Wang J, Chen J, Shen F, Huang JT, Sen S, Zhou X, Liu SM. High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer. 2014;14:643.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 31]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
63.  Chu YH, Hsieh MJ, Chiou HL, Liou YS, Yang CC, Yang SF, Kuo WH. MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma. PLoS One. 2014;9:e89930.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 41]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
64.  Zhou J, Lv R, Song X, Li D, Hu X, Ying B, Wei Y, Wang L. Association between two genetic variants in miRNA and primary liver cancer risk in the Chinese population. DNA Cell Biol. 2012;31:524-530.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 53]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
65.  Xiang Y, Fan S, Cao J, Huang S, Zhang LP. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep. 2012;39:7019-7023.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 94]  [Cited by in F6Publishing: 83]  [Article Influence: 6.9]  [Reference Citation Analysis (0)]
66.  Pettinelli P, Arendt BM, Teterina A, McGilvray I, Comelli EM, Fung SK, Fischer SE, Allard JP. Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease. PLoS One. 2018;13:e0205747.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 46]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
67.  Udali S, Guarini P, Ruzzenente A, Ferrarini A, Guglielmi A, Lotto V, Tononi P, Pattini P, Moruzzi S, Campagnaro T, Conci S, Olivieri O, Corrocher R, Delledonne M, Choi SW, Friso S. DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma. Clin Epigenetics. 2015;7:43.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 61]  [Cited by in F6Publishing: 76]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
68.  Liu J, Yang HI, Lee MH, Jen CL, Hu HH, Lu SN, Wang LY, You SL, Huang YT, Chen CJ. Alcohol Drinking Mediates the Association between Polymorphisms of ADH1B and ALDH2 and Hepatitis B-Related Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016;25:693-699.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 21]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
69.  Gaviria-Calle M, Duque-Jaramillo A, Aranzazu M, Di Filippo D, Montoya M, Roldán I, Palacio N, Jaramillo S, Restrepo JC, Hoyos S, Navas MC. Polymorphisms in alcohol dehydrogenase (ADH1) and cytochrome p450 2E1 (CYP2E1) genes in patients with cirrhosis and/or hepatocellular carcinoma. Biomedica. 2018;38:555-568.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
70.  Ranjha R, Meena NK, Singh A, Ahuja V, Paul J. Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs. PLoS One. 2017;12:e0173447.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 10]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]